-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies From the G-MAB Library
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies From the G-MAB Library
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal. The full publication is available at:
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors ("TKIs"), fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVISHIELD™ and COVIDROPS™; and diagnostic test solutions, including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners; risks related to seeking regulatory approvals and conducting clinical trials; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its product candidates' strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Media and Investor Relations
Contact: Brian Cooley
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
©2022 Sorrento Therapeutics, Inc. All Rights Reserved.
圣迭戈,9月2022年3月15日(环球网)--索伦托治疗公司(纳斯达克代码:SRNE,“索伦托”)今天宣布发表同行评审数据,详细介绍了索伦托G-MAb™文库中具有抗SARS-CoV-2中和活性的抗体的发现和临床前特征体外培养和体内在《科学报告》中,《自然》投资组合期刊。该刊物的全文可在以下网址查阅:
关于索伦托治疗公司
索伦托是一家临床和商业阶段的生物制药公司,正在开发治疗癌症、疼痛(非阿片类药物治疗)、自身免疫性疾病和新冠肺炎的新疗法。索伦托的多模式、多管齐下的抗癌方法是由于其广泛的免疫肿瘤学平台,包括关键资产,如下一代酪氨酸激酶抑制剂(TKI)、完全人类抗体(“G-MAb™文库”)、免疫细胞疗法(“DAR-T™”)、抗体-药物结合物(“ADCs”)和溶瘤病毒(“Sepretivec™”)。索伦托还在开发针对冠状病毒的潜在抗病毒疗法和疫苗,包括STI-1558、CoVISHIELD™和COVIDROPS™;以及诊断测试解决方案,包括COVIMARK™。
索伦托致力于改善患者的生活疗法,这也体现在我们努力开发(TRPV1激动剂)非阿片类疼痛管理小分子树脂毒素(RTX)和SP-102(10毫克地塞米松磷酸钠粘胶)(SEMDEXA™),这是一种广泛用于硬膜外注射的皮质类固醇的新型粘性凝胶配方,用于治疗腰骶神经根性疼痛或坐骨神经痛,并使之商业化。®(利多卡因局部系统)1.8%用于治疗带状疱疹后遗神经痛(PHN)。RTX已被批准用于与癌症相关的顽固性疼痛的第二阶段试验,以及用于骨关节炎患者的第二阶段试验。SEMDEXA™的第三阶段关键试验C.L.E.A.R.计划的积极最终结果于2022年3月宣布,该计划是一种治疗腰骶神经根性疼痛(坐骨神经痛)的新型非阿片产品。兹特里多®于2018年2月28日获得FDA批准。
有关更多信息,请访问
前瞻性陈述
根据1995年《私人证券诉讼改革法》第21E节的安全港条款,本新闻稿以及在任何陈述或会议期间所作的任何陈述都包含与索伦托治疗公司有关的前瞻性陈述,这些陈述受风险和不确定因素的影响,这些风险和不确定因素可能会使实际结果与预期的结果大不相同。前瞻性陈述包括有关对索伦托公司及其子公司的技术和候选产品的期望的陈述。可能导致我们的实际结果与前瞻性声明中表述的结果大相径庭的风险和不确定性,包括但不限于:与索伦托及其子公司、关联公司和合作伙伴的技术和前景以及与合作伙伴的合作有关的风险;与寻求监管批准和进行临床试验有关的风险;与利用其员工、子公司、关联公司和合作伙伴的专业知识帮助索伦托执行其候选产品战略的风险;与新冠肺炎的全球影响相关的风险;以及索伦托最近向美国证券交易委员会提交的定期报告中描述的其他风险,包括索伦托截至2021年12月31日的年度10-K表格报告和随后提交给证券交易委员会的10-Q表格季度报告,包括这些文件中列出的风险因素。告诫投资者不要过度依赖这些前瞻性陈述,这些前瞻性陈述仅在本新闻稿发布之日发表,除非法律要求,否则我们没有义务更新本新闻稿中的任何前瞻性陈述。
媒体和投资者关系
联系人:布莱恩·库利
电子邮件:MediaRelationship@sorrentoTreateutics.com
索伦托®和索伦托标识是索伦托治疗公司的注册商标。
G-MAB™、DAR-T™、Sepreprevec™、SOFUA™、COVISHIELD™、COVIDROPS™、COVI-MSCC™、COVIMARK™和FUJOVEE™是索伦托治疗公司的商标。
SEMDEXA™(SP-102)是赛姆努尔制药公司的商标。美国食品和药物管理局计划对其专有名称进行审查。
兹特里多®是Scilex制药公司拥有的注册商标。
所有其他商标都是其各自所有者的财产。
©2022索伦托治疗公司版权所有。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧